Tag Archives: IMMU

Blue Horseshoe Stocks: Potential Bottom-Plays & More

Posted on by


Potential Rebound Plays

U.S. Stem Cell, Inc. USRM  -We caught USRM for some nice gain opportunities a couple of weeks back. We had initially begun tracking this play after mentioning it on the morning of February 27th. Subsequent to that, we had witnessed an impressive run from a low of .014  to .0545, for a 289% gain in a span of just two sessions.

That was followed by an expected period of consolidation, but it appears as if USRM has found support at .0175. We’re going to want to return to monitoring this play more closely on the chance that it could be gearing up for another run. If it produced a move even a fraction of what we saw before, it will be worth its slot on our watchscreens.

______

Iconic Brands, Inc. ICNB – Speaking of familiar plays that could be in line for a rebound in upcoming sessions, we want to swing back around to ICNB this week. We had tracked this one to some decent gains after tagging it for observation on January 24th. Following that, the stock would trade in a range from .018 up to .0339, a respectable move of 88%

But like the above-mentioned stock, after its run, it basically underwent a big-time consolidation which lasted nearly a whole month. That brings us up to yesterday, when we noticed ICNB giving off something of a rebound signal. We’ll go back to watching more closely in the next few sessions.

Aralez Pharmaceuticals, Inc. ARLZ – Bottom Watcher

ARLZ has been falling off a cliff this week, and despite the fact that it may yet have further to fall, we’re going to want to begin monitoring it as it attempts to sniff out a solid support level. There could definitely be some opportunities waiting for traders that can properly time the recovery.


Direxion Daily Jr Gld Mnrs Bull 3X ETF  (JNUG) – Reminder

Apart from some quick chances for early gains yesterday, our freshly formulated options idea for JNUG may need some time to mature. That’s why we chose an expiration date a couple of weeks out. We’ll continue to have the JNUG 03/31 $7-8 Calls on our radars moving forward.

Extended Watchlist:
DTII, AVXL, AXAS, OWCP, SPCL, IMMU, CVRS

Incoming search terms:

  • usrm stock chat
  • immu stock blog
  • Penny stock usrm trading performance ytd

Blue Horseshoe Stocks: Reviewing IMMU, EBIO & More

Posted on by

Immunomedics, Inc. IMMU

We began tracking IMMU last month, mentioning it for the first time on May 13th, and then again in a followup on the 20th. Our timeliness in bringing what was already a steady climber to the table, as you can plainly see on the chart below.

It’s been a solid few weeks for the stock since that time. It has risen from our observed low of 3.59 to a new high of 5.44 yesterday, marking a solid 52% PPS increase in just a short time. We can also see that the volume has been steadily creeping up as well.

The last time the stock was this overbought, we saw a leveling out but not much of a consolidation. We’ll look for a similar phenomenon to occur from this point forward, and for IMMU to ultimately continue its general uptrend until we see evidence to the contrary.

Eleven Biotherapeutics, Inc. EBIO

Speaking of plays we called last month that have enjoyed extended moves up, we’ve also got on update on EBIO this morning. We tagged this stock for observation in the first week of May, and would catch it trading at a low of .80.

From there it’s been a fairly steady climb, and yesterday it too shot to new highs. As of yesterday’s top mark of 2.10, we’d witnessed a one-month rise of 163% as the stock temporarily cracked through the 200DMA. We’ll look for it to hold support at or above previous resistance in the 1.70 area on any pullbacks.

Fresh Options Idea

For a closing idea on this short week, we’ve taken notice of the chart on iShares Silver Trust SLV. It’s gapping up moderately in the premarket this morning after recently bouncing off of its lowest price in a couple of months.

Accordingly, today we’re going to look to possibly take advantage of the activity in the SLV $15-16 Weekly Calls* for intraday flip opportunities.
___

*Caution: As always, heed our caution with regard to trading options contracts with a weekly expiration on Friday. It’s something only to be attempted by advanced traders!

Extended Watchlist:
GDSI, SNST, SIGA SAND, AUY, USLV

Blue Horseshoe Stocks: PLCE Options Recap & More

Posted on by

The Children’s Place, Inc. PLCE – Options Review

The first thing we want to mention this morning is the performance our running options idea for PLCE that we formulated earlier in the week. We continued to stay on the trail of PLCE Weekly $70-75 Calls in yesterday’s premarket report, even after they had provided us with chances at gains ranging from 112-315% in the prior session.

Despite the $75′s being a bit too far out of the money for any notable action, the other two contracts from within our target sets performed solidly once again.

The $70 Calls traded in a daily range from 2.85-3.70, which marked an intraday rise of 30% The $72.50′s fared even better, running from a low of .65 to a high of 1.30, marking an even 100% rip and the second consecutive session wherein the stock provided the opportunity at at least a double-bagger.

Immunomedics, Inc. IMMU

We tagged IMMU for observation on Friday of last week, and since that time the stock has made an appreciable swing to the upside. Our observed low on the stock is 3.59, which gave way to a new high of 4.25 yesterday. That represents a modest yet notable 18% increase.

We’ll want to continue to monitor the activity in this play which will hold our interest moving forward, provided it can maintain support at or above its previous resistance point of 4.00 on any pullbacks.

MORRIS PLAINS, N.J., May 19, 2016 (GLOBE NEWSWIRE) — Immunomedics, Inc. (Nasdaq:IMMU) today announced that the Scientific Program Committee of the American Society of Clinical Oncology (ASCO) has selected two of the Company’s abstracts for oral presentation at two Clinical Science Symposium Sessions during their 2016 Annual Meeting, scheduled for June 3-7, 2016 at McCormick Place Convention Center in Chicago, Illinois. (>>View PR)

Global Equity International, Inc. GEQU

GEQU has proven to be a solid winner for us in the past. We recently re-tagged it at a perfect time on 11th of this month, just as it was coming off a bottom. We saw the stock  trading as low as .0123 yesterday it closed at a new high of .03, which goes down as a 144% swing.

We’ll keep our eyes on this one as well, in the event it can maintain support above the 200DMA of .0235.

Extended Watchlist:
UAMM, ASTI, NWMH, TTCM, FDIT

Blue Horseshoe Stocks: News Update, Options Highlights & More

Posted on by

Aperture Health, Inc. APRE – News Update

Our first order of business this morning is to update our readers on APRE, which we’ve been following for the better part of a month. In that time the stock has provided us with multiple swing trade opportunities and has been stretching the envelope on its latest upswing. From the .0188 swing-low we observed last Wednesday APRE has rapidly gained 219%, running up to a new high of .0599 yesterday.

We’ve pointed out a few key highlights of the current chart on the following snapshot:

We also want to point out some untraded-upon news that hit the wires yesterday post-market:

NEW YORK, May 12, 2016 /PRNewswire/ – Aperture Health, Inc. (OTC Markets.com: APRE) and CSS Alliance LLC (“CSS”), are pleased to announce that the company has branched out and signed a Joint Venture agreement which includes an exclusive worldwide distribution agreement with CSS Korea R&D Co., Ltd for new technologies and products that include solar powered A/C units, and powerless generators, as well as solar powered boilers (>>View Full PR)

Options Highlights

Jack in the Box, Inc. JACK - We had a couple of our active options targets turn up sizable opportunities for profits yesterday beginning with JACK 05/20 $70 and $75 Calls. We caught JACK on the heels of its Q2 earnings release, and various circumstances allowed for us to take advantage of the idea on its first day of mentioning.

The $70 Calls traded in an impressive range from a low of 2.25 on up 6.85 for an intraday gain of 204% The $75 Calls fared even better as they ran from .39 to 1.61, a single-session rip of 313% With performances like those, we’ll continue to track these contracts through to their expiration next week.

______

Macy’s Inc. M  – Our signaled range for Macy’s from Wednesday’s report added to its gains yesterday. We had been tracking the M Weekly $36-34 Puts. At the top of the range, the $36 Puts surged from a low of 1.83 up to 5.15, for a two-session swing of 181% Gains increased incrementally into the lower strike prices, culminating in the $34′s which traded up from Wednesday’s low of .50 to a new high of 3.62; a 624% swing.

Cerebain Biotech Corp. CBBT

Just after we were reviewing CBBT’s recent performance in yesterday’s morning report, (We’d added it to our radars last Tuesday) the stock went on to set another new high for us.

The stock traded in a daily range from 1.25-1.75, a respectable 40% intraday rip. From our observed low of .53, the new high represents an overall move of 230%

Extended Watchlist:
QUTR, IMMU, IDRA, XXII, NVDA, MOMO

PROW, RNN & Extended Watchlist

Posted on by
Record-Setting ‘Green Rush’ Begins to Subside
-
Like all good things, the frenzied buying of countless pot stocks largely came to an end during yesterday’s session. It was a historic week; an overwhelming trend caused by sheer excitement over Colorado’s precedent-setting entry into the post-prohibition era, and we were happy to cover every step, taking profits along the way! Granted, the main wave of hysteria is now over, but our continued interest in the sector as a whole will not wane. As we stated previously, this story has only just begun to be written. Even as many of the huge runners we’ve tracked began to pull back, others maintained their trends, and still others came down to find support only to rebound and provide bounce opportunities. Rest assured, we will remain hot on the trail of any possible chance at added profits within this sector that has been so good to us for so long a time. For now, it’s time to shift gears and talk about some of our other interests that were forced to the back burner in all the excitement.

Progress Watch Corp. PROW

PROW has brought us some really impressive gains in the short time that we’ve been including it in our reports. When we first began talking about it (12/20/13, trading at .0065) we were especially interested in its tight share structure. That day, we said that the 50DMA rising sharply toward the 200DMA “should lead to a golden cross in the weeks and months ahead.”  That golden cross is now in progress as the stock ran into the close yesterday, attaining four cents, an increase of 515% off of the bottom we observed just twelve trading sessions ago.

As the value of the stock increases, we’re going to be looking for support levels to hold at areas of previous resistance. In the event of any pullbacks, we would like to see support hold at .025, and below that, .013, in order to remain bullish on PROW.

Rexhan Pharmaceuticals, Inc. RNN

Back on December 11th, we tagged RNN for the first time in our extended watchlist, and were rewarded with an intraday run of 26% from .4026 to  .5179. Even as marijuana stocks were breaking out over the past couple of days, we were still tracking this stock’s impressive run via our extended watchlists, and yesterday, saw a high of .765. That marks an increase of 90% from our observed low, a figure which is being pushed even higher this morning; pre-market trades have gone off as high as .929, so things could get very interesting from here. This spike seems to have been catalyzed by a recent press announcement from RNN.


The following PR was released under the headline: “RX-3117 has Shown Efficacy Against Gemcitabine-Resistant Human Cancer Cell Lines and a Broad-Spectrum of Anti-Cancer Activity “

ROCKVILLE, Md., Jan 08, 2014 (BUSINESS WIRE) — Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company, announced today the initiation of a Phase Ib clinical trial to study the safety and efficacy of RX-3117 in cancer patients with solid tumors. RX-3117 is a next-generation cancer cell specific drug candidate that possesses a broad spectrum of anticancer activity with reduced side effects. In an exploratory Phase I clinical trial conducted in Europe, RX-3117 demonstrated oral bioavailability, and safety and tolerability in cancer patients with solid tumors. >> FULL PR

Extended Watchlist:
CNAT, BBRY, IMMU, BLDP, NSPH, RTRX